Phase I Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 May 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions
- 02 May 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 02 May 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2016 New trial record